CANN
GROUP LIMITED

ASX ANNOUNCEMENT

26 JULY 2018

CANN GROUP RELOCATES CORPORATE HEADQUARTERS TO WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH AT LA TROBE UNIVERSITY

26 July 2018 – Cann Group Limited (ASX: CAN) is pleased to announce it has relocated its corporate headquarters and registered office to be located at the Walter and Eliza Hall Institute of Medical Research at La Trobe University in Bundoora, Victoria.

Cann Group CEO Peter Crock said while the company will remain in the La Trobe University precinct, the move enables the company to continue its rapid expansion.

"The move into the Walter and Eliza Hall Institute facility is an important progression while maintaining Cann's close relationship with La Trobe University. We have seen considerable growth in staff numbers this year, and with this number expected to continue rising, we have now secured an appropriate base to support our ongoing growth."

Registered office address:
Cann Group Limited
4 Research Drive
Walter and Eliza Hall Institute Building
Bundoora, Victoria, 3083

For further information please contact:

Peter Crock
Cann Group Limited
+61 (0) 3 9095 7088
contact@canngrouplimited.com

Matthew Wright
NWR Communications
+61 (0) 451 896 420
matt@nwrcommunications.com.au

About Cann Group

Cann Group is building a world-class business focused on breeding, cultivating and manufacturing medicinal cannabis for sale and use within Australia. The company has established research and cultivation facilities in Melbourne and is striving to provide access to medicinal cannabis for Australian patients. Cann Group has executed collaboration agreements that will enable it to establish a leading position in plant genetics, breeding, extraction, analysis and production techniques required to facilitate the supply of medicinal cannabis for a range of diseases and medical conditions. It was issued with Australia's first medicinal cannabis research licence in February 2017, in addition to Australia's first medicinal cannabis cultivation licence in March 2017. Aurora Cannabis Inc – one of Canada's largest listed medicinal cannabis companies – is a cornerstone investor in Cann, with a 22.9% shareholding.